Triple-negative breast cancers (TNBCs) are characterized by a poor prognosis and lack of
targeted treatments, and thus, new therapeutic strategies are urgently needed. Inhibitors …

Triple negative breast cancer (TNBC) is the most aggressive type of breast cancer, which
shows resistance to common breast cancer therapies, as it lacks the expression of the most …

Objectives: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer,
and there is no approved targeted therapy. We studied the expression of programmed cell …

Purpose: Programmed death ligand 1 [PD-(L) 1]-targeted therapies have shown modest
survival benefit in triple-negative breast cancer (TNBC). PD-L1+ microenvironments in …

Background To date, there are no effective therapeutic targeting agents for triple-negative
breast cancer (TNBC), and PD-L1 has presented potential as an effective marker of …

Background Programmed cell death ligand 1 (PD-L1) is a potential predictive biomarker of
the response to anti-PD-L1/anti-programmed cell death 1 (PD-1) therapy in multiple cancers …

Triple-negative breast cancer (TNBC) is an invasive tumor with a high incidence of distant
metastasis and poor prognosis. In TNBC cells, high PD-L1 expression can induce an …

Although the immune checkpoint role of programmed death ligand 1 (PD-L1) has been
established and targeted in cancer immunotherapy, the tumor-intrinsic role of PD-L1 is less …

Background Triple negative breast cancer (TNBC) has higher rates of recurrence and distant
metastasis, and poorer outcome as compared to non-TNBC. Aberrant activation of WNT …

Early-phase trials targeting the T-cell inhibitory molecule programmed cell death ligand 1
(PD-L1) have shown clinical efficacy in cancer. This study was undertaken to determine …